MX2020011697A - Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario. - Google Patents
Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario.Info
- Publication number
- MX2020011697A MX2020011697A MX2020011697A MX2020011697A MX2020011697A MX 2020011697 A MX2020011697 A MX 2020011697A MX 2020011697 A MX2020011697 A MX 2020011697A MX 2020011697 A MX2020011697 A MX 2020011697A MX 2020011697 A MX2020011697 A MX 2020011697A
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric antigen
- antigen receptors
- natural killer
- immune checkpoint
- killer cells
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 2
- 230000005746 immune checkpoint blockade Effects 0.000 title 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 abstract 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan en la presente métodos para producir células NK que expresan receptores de antígeno quimérico y que no tienen expresión de CISH. Se proporcionan además métodos para tratar enfermedades al administrar las células CAR NK.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862666665P | 2018-05-03 | 2018-05-03 | |
US201862666965P | 2018-05-04 | 2018-05-04 | |
PCT/US2019/030721 WO2019213610A1 (en) | 2018-05-03 | 2019-05-03 | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011697A true MX2020011697A (es) | 2020-12-10 |
Family
ID=68386134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011697A MX2020011697A (es) | 2018-05-03 | 2019-05-03 | Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210230548A1 (es) |
EP (1) | EP3788061A4 (es) |
JP (2) | JP2021522798A (es) |
KR (1) | KR20210005240A (es) |
CN (1) | CN112292390A (es) |
AU (1) | AU2019262218A1 (es) |
BR (1) | BR112020022010A2 (es) |
CA (1) | CA3099342A1 (es) |
CO (1) | CO2020015168A2 (es) |
MX (1) | MX2020011697A (es) |
SG (1) | SG11202010763VA (es) |
WO (1) | WO2019213610A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100083150A (ko) | 2007-09-18 | 2010-07-21 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | 노로바이러스에 대한 보호면역반응을 제공하는 방법 |
EA035442B1 (ru) | 2011-07-11 | 2020-06-17 | Такеда Вэксинс, Инк. | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
CA3079748A1 (en) | 2017-11-09 | 2019-05-16 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
JP7268039B2 (ja) | 2018-02-01 | 2023-05-02 | エヌケーマックス カンパニー リミテッド | がん治療のためのナチュラルキラー細胞および組成物の製造方法 |
KR20210013077A (ko) * | 2018-05-16 | 2021-02-03 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Cas9 리보핵단백질을 사용하는 녹아웃 일차 및 확장된 인간 nk 세포의 생성 |
CN113811604A (zh) * | 2019-03-29 | 2021-12-17 | 得克萨斯大学体系董事会 | Car-nk细胞的产生方法及其用途 |
AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン, インコーポレイテッド | 抗cd47及び抗cd20による血液癌の治療 |
US20210147799A1 (en) * | 2019-11-08 | 2021-05-20 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
KR20220108793A (ko) * | 2019-11-27 | 2022-08-03 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Msc 세포의 대규모 조합된 car 형질 도입 및 crispr 유전자 편집 |
CN115989034A (zh) * | 2019-11-27 | 2023-04-18 | 得克萨斯大学体系董事会 | Nk细胞的大规模组合car转导和crispr基因编辑 |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
WO2021202581A1 (en) * | 2020-03-30 | 2021-10-07 | WUGEN, Inc. | Engineered immune cells for adoptive cell therapy |
TW202237826A (zh) | 2020-11-30 | 2022-10-01 | 瑞士商克里斯珀醫療股份公司 | 基因編輯的自然殺手細胞 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
US20240115606A1 (en) | 2020-12-15 | 2024-04-11 | Universiteit Antwerpen | Cell-Based Therapeutics Targeting CD70 |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
CN113005151A (zh) * | 2021-03-12 | 2021-06-22 | 广东药科大学 | 一种kdr-car-nk细胞的制备方法及其应用 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN113599395B (zh) * | 2021-09-22 | 2022-08-12 | 郑州源创吉因实业有限公司 | 含有nk细胞的治疗癌症的药物组合物 |
WO2023056330A1 (en) * | 2021-10-01 | 2023-04-06 | Board Of Regents, The University Of Texas System | Antibody loaded immune cells and methods for use in cancer treatment |
WO2023062113A1 (en) * | 2021-10-15 | 2023-04-20 | Miltenyi Biotec B.V. & Co. KG | Method for the generation of genetically modified nk cells |
WO2023070079A1 (en) * | 2021-10-21 | 2023-04-27 | Board Of Regents, The University Of Texas System | Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof |
WO2023081811A1 (en) * | 2021-11-04 | 2023-05-11 | Saliogen Therapeutics, Inc. | Immune cells with chimeric antigen receptors or chimeric autoantibody receptors |
TW202338085A (zh) | 2021-11-18 | 2023-10-01 | 美商健生生物科技公司 | 用於擴增自然殺手細胞製劑之無餵養細胞培養方法 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024089622A1 (en) * | 2022-10-25 | 2024-05-02 | Takeda Pharmaceutical Company Limited | Adgre2 chimeric receptor nk cell compositions and methods of use |
WO2024100203A1 (en) * | 2022-11-10 | 2024-05-16 | Onk Therapeutics Limited | Combined therapies using immunomodulating drugs |
CN115947869B (zh) * | 2022-11-28 | 2023-12-12 | 广州佰芮慷生物科技有限公司 | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 |
CN116769722A (zh) * | 2023-07-04 | 2023-09-19 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2614151B1 (en) * | 2010-09-08 | 2019-07-24 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
EP3326467B1 (en) * | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
JP6010136B2 (ja) * | 2011-12-22 | 2016-10-19 | モガム バイオテクノロジー インスティチュート | ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物 |
CN108472314A (zh) * | 2015-07-31 | 2018-08-31 | 明尼苏达大学董事会 | 修饰的细胞和治疗方法 |
EP4253412A3 (en) * | 2015-12-16 | 2023-11-22 | The Walter and Eliza Hall Institute of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
MX2018008345A (es) * | 2016-01-11 | 2018-12-06 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia. |
KR20180101540A (ko) * | 2016-01-15 | 2018-09-12 | 이투빅스 코포레이션 | T 세포 면역요법을 위한 방법 및 조성물 |
CN109890408A (zh) * | 2016-05-27 | 2019-06-14 | 埃特彼塞斯公司 | 新表位疫苗组合物及其使用方法 |
WO2018081476A2 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
CN113811604A (zh) * | 2019-03-29 | 2021-12-17 | 得克萨斯大学体系董事会 | Car-nk细胞的产生方法及其用途 |
-
2019
- 2019-05-03 MX MX2020011697A patent/MX2020011697A/es unknown
- 2019-05-03 AU AU2019262218A patent/AU2019262218A1/en active Pending
- 2019-05-03 CN CN201980037453.2A patent/CN112292390A/zh active Pending
- 2019-05-03 WO PCT/US2019/030721 patent/WO2019213610A1/en active Application Filing
- 2019-05-03 KR KR1020207034764A patent/KR20210005240A/ko unknown
- 2019-05-03 EP EP19795874.7A patent/EP3788061A4/en active Pending
- 2019-05-03 SG SG11202010763VA patent/SG11202010763VA/en unknown
- 2019-05-03 BR BR112020022010-8A patent/BR112020022010A2/pt unknown
- 2019-05-03 US US17/050,775 patent/US20210230548A1/en active Pending
- 2019-05-03 CA CA3099342A patent/CA3099342A1/en active Pending
- 2019-05-03 JP JP2020561821A patent/JP2021522798A/ja active Pending
-
2020
- 2020-12-02 CO CONC2020/0015168A patent/CO2020015168A2/es unknown
-
2024
- 2024-01-05 JP JP2024000389A patent/JP2024045179A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3099342A1 (en) | 2019-11-07 |
AU2019262218A1 (en) | 2020-12-10 |
US20210230548A1 (en) | 2021-07-29 |
BR112020022010A2 (pt) | 2021-01-26 |
EP3788061A1 (en) | 2021-03-10 |
KR20210005240A (ko) | 2021-01-13 |
WO2019213610A1 (en) | 2019-11-07 |
CN112292390A (zh) | 2021-01-29 |
JP2024045179A (ja) | 2024-04-02 |
EP3788061A4 (en) | 2022-02-23 |
SG11202010763VA (en) | 2020-11-27 |
JP2021522798A (ja) | 2021-09-02 |
CO2020015168A2 (es) | 2021-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011697A (es) | Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario. | |
PH12019500750A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
MX2022006568A (es) | Agentes anti-cd20, agentes anti-cd22, y usos y combinaciones de los mismos con una celula que expresa un receptor de antigeno quimerico (car) de cd19. | |
MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
AR120563A1 (es) | Receptores de antígeno quimérico cd19 y cd22 y sus usos | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
MX2019011514A (es) | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. | |
MX2021015971A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
EA201992469A1 (ru) | Антигенспецифические иммунные эффекторные клетки | |
MX2019009660A (es) | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. | |
MX2021011816A (es) | Metodos para produccion de celulas car-nk y uso de las mismas. | |
MX2020006689A (es) | Composiciones de vcar y metodos de uso. | |
MX2023009421A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
WO2019094595A3 (en) | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies | |
MX2019002903A (es) | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. | |
MX2019000641A (es) | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. | |
MX2018004121A (es) | Receptores de antigeno y usos de los mismos. | |
WO2019112978A3 (en) | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof |